On Drug Prices, Harris Pushes for Deeper Cuts While Trump Offers Few Specificsnews2024-10-08T17:07:01+00:00October 8th, 2024|The New York Times|
F.T.C. Accuses Drug Middlemen of Inflating Insulin Pricesnews2024-09-20T19:16:14+00:00September 20th, 2024|The New York Times|
Hot Summer Threatens Efficacy of Mail-Order Medicationsnews2024-08-13T14:04:23+00:00August 13th, 2024|The New York Times|
South Africa Runs Out of Insulin Pens as Global Supply Shifts to Weight-Loss Drugsnews2024-06-19T09:02:12+00:00June 19th, 2024|The New York Times|
Ozempic ha transformado el tratamiento de la diabetesnews2024-05-14T12:19:23+00:00May 14th, 2024|The New York Times|
How Ozempic Is Changing Diabetes Treatmentnews2024-05-13T15:00:06+00:00May 13th, 2024|The New York Times|
Insulin Cost Is a Key Campaign Issue for Bidennews2024-05-04T09:02:14+00:00May 4th, 2024|The New York Times|
Inside Novo Nordisk, the Company Behind Ozempic and Wegovynews2024-04-20T04:01:23+00:00April 20th, 2024|The New York Times|
Your Inhalers and EpiPens Aren’t Very Healthy for the Environmentnews2024-02-26T17:10:53+00:00February 26th, 2024|The New York Times|
California’s Plan for Cheaper Insulin Collides With Big Pharma’s Price Cutsnews2023-03-24T15:25:37+00:00March 24th, 2023|The New York Times|
